Literature DB >> 21873884

Enhanced endothelial progenitor cell angiogenic potency, present in early experimental renovascular hypertension, deteriorates with disease duration.

Xiang-Yang Zhu1, Victor H Urbieta Caceres, Frederic D Favreau, James D Krier, Amir Lerman, Lilach O Lerman.   

Abstract

BACKGROUND: Endothelial progenitor cells (EPCs) augment neovascularization and repair of damaged tissues, but may undergo functional changes during exposure to cardiovascular risk factors. This study tested the hypothesis that early renovascular hypertension (RVH) modulates the temporal pattern of EPC function that deteriorates with disease duration.
METHODS: RVH was induced in domestic pigs by unilateral renal artery stenosis. EPCs were cultured after 3, 6, and 12 weeks of RVH or normal control to evaluate EPC function, growth factor, and homing receptor expression. Plasma renin activity (PRA), vascular endothelial growth factor (VEGF), and its soluble receptor-1 (sFlt-1) were measured in plasma. EPCs (10 × 10) isolated from 3-week RVH or from normal pigs were also injected into control kidneys (n = 6-7, each group), and 4 weeks later single-kidney renal blood flow (RBF) and glomerular filtration rate (GFR) were evaluated. Microvascular density was studied ex vivo using microcomputed tomography.
RESULTS: Blood pressure peaked at 3 weeks and remained higher than normal throughout the study. Systemic PRA also peaked after 3 weeks of RVH and declined thereafter, whereas sFlt-1 showed a reciprocal pattern. In vivo, only RVH but not normal EPCs increased RBF, GFR, and microvascular density. RVH-EPCs showed in vitro enhanced proliferation, tube formation, VEGF, and homing receptor expression that peaked at 3 weeks, which were abolished by valsartan and returned to baseline levels after 12 weeks of RVH. EPC number remained unchanged throughout the study.
CONCLUSION: A transient enhancement of EPC function, mediated by angiotensin II, may contribute to compensatory vascular adaptation in early RVH, but is lost as hypertension persists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873884      PMCID: PMC3634099          DOI: 10.1097/HJH.0b013e32834ae611

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  34 in total

1.  Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension.

Authors:  F M Belgore; A D Blann; F L Li-Saw-Hee; D G Beevers; G Y Lip
Journal:  Am J Cardiol       Date:  2001-03-15       Impact factor: 2.778

2.  Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.

Authors:  M Vasa; S Fichtlscherer; A Aicher; K Adler; C Urbich; H Martin; A M Zeiher; S Dimmeler
Journal:  Circ Res       Date:  2001-07-06       Impact factor: 17.367

3.  Circulating endothelial progenitor cells, vascular function, and cardiovascular risk.

Authors:  Jonathan M Hill; Gloria Zalos; Julian P J Halcox; William H Schenke; Myron A Waclawiw; Arshed A Quyyumi; Toren Finkel
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

4.  Enhanced renal cortical vascularization in experimental hypercholesterolemia.

Authors:  Michael D Bentley; Martin Rodriguez-Porcel; Amir Lerman; Mirit Hershman Sarafov; J Carlos Romero; Laura I Pelaez; Joseph P Grande; Erik L Ritman; Lilach O Lerman
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

5.  Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization.

Authors:  Jun-ichi Yamaguchi; Kengo Fukushima Kusano; Osamu Masuo; Atsuhiko Kawamoto; Marcy Silver; Satoshi Murasawa; Marta Bosch-Marce; Haruchika Masuda; Douglas W Losordo; Jeffrey M Isner; Takayuki Asahara
Journal:  Circulation       Date:  2003-03-11       Impact factor: 29.690

6.  Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro.

Authors:  E N Haugen; A J Croatt; K A Nath
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

7.  Angiotensin II and angiotensin-(1-7) decrease sFlt1 release in normal but not preeclamptic chorionic villi: an in vitro study.

Authors:  Lauren Anton; David C Merrill; Liomar A A Neves; Courtney Gruver; Cheryl Moorefield; K Bridget Brosnihan
Journal:  Reprod Biol Endocrinol       Date:  2010-11-04       Impact factor: 5.211

8.  Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells.

Authors:  Toshio Imanishi; Takuzo Hano; Ichiro Nishio
Journal:  Hypertens Res       Date:  2004-02       Impact factor: 3.872

9.  Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis.

Authors:  Alejandro R Chade; Martin Rodriguez-Porcel; Joseph P Grande; Xiangyang Zhu; Vincenzo Sica; Claudio Napoli; Tatsuya Sawamura; Stephen C Textor; Amir Lerman; Lilach O Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-15       Impact factor: 8.311

10.  Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways.

Authors:  Radia Tamarat; Jean-Sébastien Silvestre; Micheline Durie; Bernard I Levy
Journal:  Lab Invest       Date:  2002-06       Impact factor: 5.662

View more
  14 in total

1.  Preserved endothelial progenitor cell angiogenic activity in African American essential hypertensive patients.

Authors:  Seo Rin Kim; Alfonso Eirin; Sandra M S Herrmann; Ahmed Saad; Luis A Juncos; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Nephrol Dial Transplant       Date:  2018-03-01       Impact factor: 5.992

Review 2.  Restoring the renal microvasculature to treat chronic kidney disease.

Authors:  David A Long; Jill T Norman; Leon G Fine
Journal:  Nat Rev Nephrol       Date:  2012-02-07       Impact factor: 28.314

3.  Endothelial outgrowth cells shift macrophage phenotype and improve kidney viability in swine renal artery stenosis.

Authors:  Alfonso Eirin; Xiang-Yang Zhu; Zilun Li; Behzad Ebrahimi; Xin Zhang; Hui Tang; Michael J Korsmo; Alejandro R Chade; Joseph P Grande; Christopher J Ward; Robert D Simari; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-21       Impact factor: 8.311

4.  Adjunctive mesenchymal stem/stromal cells augment microvascular function in poststenotic kidneys treated with low-energy shockwave therapy.

Authors:  Xiao-Jun Chen; Xin Zhang; Kai Jiang; James D Krier; Xiangyang Zhu; Sabena Conley; Amir Lerman; Lilach O Lerman
Journal:  J Cell Physiol       Date:  2020-05-19       Impact factor: 6.384

5.  Preserved function of late-outgrowth endothelial cells in medically treated hypertensive patients under well-controlled conditions.

Authors:  Zhi Chen; Sandra M S Herrmann; Xiangyang Zhu; Kyra L Jordan; Monika L Gloviczki; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Hypertension       Date:  2014-07-21       Impact factor: 10.190

Review 6.  Paradigm Shifts in Atherosclerotic Renovascular Disease: Where Are We Now?

Authors:  Stephen C Textor; Lilach O Lerman
Journal:  J Am Soc Nephrol       Date:  2015-04-13       Impact factor: 10.121

7.  Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease.

Authors:  Alejandro R Chade; Nathan Tullos; Nicholas J Stewart; Bret Surles
Journal:  J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 10.121

Review 8.  Gained in translation: protective paradigms for the poststenotic kidney.

Authors:  Lilach O Lerman; Stephen C Textor
Journal:  Hypertension       Date:  2015-02-23       Impact factor: 10.190

Review 9.  Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease.

Authors:  Yujiro Kida; Bie Nga Tchao; Ikuyo Yamaguchi
Journal:  Pediatr Nephrol       Date:  2013-03-10       Impact factor: 3.714

10.  Association of circulating progenitor cells with angiotensin II in newly diagnosed hypertensive patients.

Authors:  Maria W Skrzypkowska; Monika E Ryba-Stanisławowska; Bartosz Słomiński; Piotr G Gutknecht; Janusz Siebert; Jolanta M Myśliwska
Journal:  J Hum Hypertens       Date:  2017-11-30       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.